Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 4/20 | 0.55 |
| ▸ | COPS5 | Q92905 | 4/20 | 0.55 |
| ▸ | EGFR | P00533 | 9/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074807 | 0.78 | EGFR (0.50) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL559673 | 0.77 | EGFR (0.48) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL10765869 | 0.75 | EGFR (0.47) | EGFRTRPV1PIK3CDPIK3CALMNA | |
| SCHEMBL276425 | 0.75 | EGFR (0.47) | PSMD14EGFRTRPV1PIK3CDPIK3CA | |
| SCHEMBL7989490 | 0.75 | EGFR (0.47) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL12747762 | 0.75 | EGFR (0.47) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL2008884 | 0.75 | CYP3A4 (0.47) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL2008880 | 0.75 | EGFR (0.47) | EGFRTRPV1PIK3CDPIK3CAKDM4E | |
| SCHEMBL276426 | 0.75 | METAP2 (0.55) | EGFRTRPV1KDM4ELMNACYP1A2 | |
| SCHEMBL18914606 | 0.75 | EGFR (0.47) | EGFRTRPV1PIK3CDPIK3CAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-08-21 | — | — | US | claimed |
| EP-2710119-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | Cleave Biosciences, Inc. (US) | 2014-03-26 | — | — | EP | claimed |
| WO-2012158435-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | ZHOU HAN-JIE (US) | 2012-11-22 | — | — | WO | claimed |
| EP-3663283-B1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THIN FILM FORMED FROM THE COMPOSITION | SAMSUNG DISPLAY CO LTD (KR) | 2021-11-03 | — | — | EP | disclosed |
| EP-3339395-B1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2019-10-02 | — | — | EP | disclosed |
| EP-3339395-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2018-06-27 | — | — | EP | disclosed |
| EP-3301097-A2 | [1]BENZOTHIENO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) | Samsung Display Co., Ltd. (KR) | 2018-04-04 | — | — | EP | disclosed |
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2014066506-A2 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2014066506-A2 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| EP-2710119-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | Cleave Biosciences, Inc. (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012158435-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | ZHOU HAN-JIE (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | USP24, USP36, USP39 | PSMD14 7/4885COPS5 39/4885EGFR 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.